Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
She has brilliant communication skills, massive experience and a wide range of contacts from her industry experience.
Change was needed. I believe she will be a breath of fresh air. As for the opening price for the share - that is irrelevant for the long term picture.
GLA
Nasdaq here we come
Ideal person to drive our strategy and present the Company's truly innovative technology to the specialist healthcare investor audience, especially in the US
Could have opened worse than 47 p I suppose
Finnish blue.
It's now clear AS leaving was part of the 50p raise package offered to the insti's. It was pretty much the only bargaining chip that Avacta had in play after royally fecking things up over the years.
No-one would give a dime if he was still in charge.
I believe CC was a big influence in adapting the trial strategy. She is very focussed. I also think the two promotional videos have been her idea and I think they have been excellent.
We have been crying out for better communications and she is addressing that.
GLA
We have already seen her input...even before this announcement.
Website changes
Videos introduced fronted by her
Presentations made
This is not about AS f***ing up...all the major decisions will have had Board approval and were not done in isolation.
This is about now having a CEO on board with CONTACTS and the first real indication the company now has a focused strategy which has been put in place due to the excellent results seen so far in the AVA6000 trial...Networking, networking, networking...she can talk to the players we now need to be talking to...she brings a much bigger picture to the company especially when it comes to Oncology and the US.
What we don't know is what information/feedback Avacta is getting from our existing Partners. From their comments Point sounds secure after the sales to EL...which was a possible concern our Agreement could have been terminated. We also don't know what discussions have taken place with the FDA and what favourable comments have come to pass there.
This mornings reaction is what often happens once Results are issued...no surprises there.
I still don't understand why it is assumes DX will be sold...as I've said there are other possibilities which might be considered. Why sell off a business which can use our Affimers in their products. TX is going to become an Oncology only business with Precision and Affimers...DX can be Spun Off as a completely separate entity and that can take forward Affimers in DX.
The Board has made the decision to change the CEO and our Board Chairman is EF who has just been made CEO of Levicept which is basically funded and run by 4 major Investment Funds who know their stuff...watch this space...
Bella - why not divest Dx and license the Affimers to the buyer ?
Unless you are very familiar with the industry, an insider, stay well away from this sector of the market.
Full of pump and dump, jam tomorrow, insider trading, lies and manipulation. Famous for it.
If a mine is a hole in the ground, with a liar standing next to it, then a pharma minnow is snakeoil, touted as a cure for cancer.
Beware. The technical chart looks like a trainwreck, and even this ' great ' news has not inspired the SP to move.
Straight in the bin Kat - another completely clueless charter.
The night is always darkest before the dawn
Share price at all time lows with a new ceo and multiple commercial routes to be realised shortly.
Thanks for the warning much appreciated… you can move along now though… might as well go save many people on all the BB’s with technical analysis. 👋
Kat
This RNS announces a new leader, not who what where when and how the new leader will lead.
This is what the market will be waiting for, and the sp will reflect that.
Looks like the sellers have cleared. Back up into the 50s.
Off you trot. Kat your bus is outside
Be very suspicious of the Hoopla. This has 141 chats, top of the chat board, which piqued my interest, so I stroll over and find.
Ramping and cheerleading over, as B2HS2L says, the announcement of a new leader. From the hype, you would think it's the Second Coming.
This, in my experience, is a bad sign. A crew is trying to offload stock, hence the ballyhoo. Look at the chart, this is a risky microstock, with finance problems, a track record of failure and poor strategy. Don't believe the hype, be drawn in and get left holding the bag.
Saint 68...A Spin off is a form of divesting...DX is funded...market can determine valuations of each company...DX and TX function as two separate companies but can have same Board members and same shareholders. If TX goes for a dual listing then DX doesn't have to... There are so many advantages.
Let's see,,,
Kat, what do you know about this company? Tell us about its lead asset.
I know the same as you; what is in the public sphere and released by RNS and press.
And you've been interested in this stock for 10 minutes, - 15 at most..
Oh no....not another blind faith crayon muncher..zzzzz.
So what is the lead asset? What are its clinical advantages? Those are simple questions. If you don't know the answers, you know nothing about this company and your opinions are less than worthless.
Enough about the generic warnings we are all adults.
Any thoughts on the below.
Can you explain what you know about high Fap, Dox sensitive tumours and our upcoming next drug candidate AVA3996?
What results do you expect from first line patients in the 2w study?
Any thoughts on the case study and partial response within the AVA6000 3w study?
Stop biting. Ignore it.
Back on topic. Bye Alan. As has been said, I imagine that CC has been in charge of strategy for the platform since her arrival. I'm pleased to see the shumper wearer out the door, thanks for getting it in the clinic, it's time to move on. Next up, TG out, she'll need to backfill and strengthen the board, decide what to do with Dx and continue the Tx progress. Good luck to her.